C-3QK2Restem
UMPCs, NK cells, immune modulation
modulatingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-3QK2
C-3QK2C-3QK2UMPCs, NK cells, immune modulation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell product (ULSC) performs when treating Facioscapulohumeral Muscular Dystrophy (FSHD) 1 or 2. It will assess safety and preliminary efficacy in relieving symptoms of FSHD with ULSC administered in two intravenous (IV) doses of 100 million cells per dose. The main questions that this study plans to answer are: * Is ULSC as safe as placebo (a look-alike saline without cells) in repeated IV infusion? * Does ULSC improve symptoms of FSHD after each dose? Researchers will compare ULSC to placebo. Participants will: * Have been diagnosed with FSHD of a Ricci clinical severity score 3 or more. * Participate in this study for total duration of 21 months with 11 in-person visits and 5 virtual visits. * Visit the clinic for a total of 4 IV infusions (250 mL) 3 months apart. * Receive 2 doses of ULSC and 2 doses placebo in either of two sequences, as assigned: ULSC first (Day 0 and Month 3) and placebo second (Month 6 and Month 9), or placebo first (Day 0 and Month 3) and ULSC second (Month 6 and Month 9). * Return for follow-up visits after each dose and up to 12 months after final dose.
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue derived mesenchymal stem cells (MSC), with intravenous (IV) administration in hospitalized patients with acute respiratory distress syndrome (ARDS) due to COVID-19.
Wolters Kluwer Note: Since your browser does not support JavaScript, you must press the Resume button once to proceed.
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > stream x��]ێ$�q}ﯨg�KF� ,��� ��� ��`�e���LfUfUF�̌j�-͠����Oo������,�3\~����|� ?��҇����W����|��Wx����ϓ k|����� ^~�
RESTEM Receives FDA Orphan Drug Designation for its ULSC Program for the Treatment of Polymyositis and Dermatomyositis | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture Sports More More Latest in More Real Estate Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX 0.37 % S&P 500 -0.05 % DOW -0.09 % NASDAQ -0.24 % Oil -3.74 % Dollar 0.05 % Gold 1.2 % tsx movers: CNQ-T -0.3 % BB-T … s International (TSOI) announced today filing of a new Phase III clinical trial application with the FDA for use of its JadiCell adult stem cells in treatment of acute respiratory distress syndrome (ARDS). This investigational drug application (IND) is based on the Company’s existing data and experiences associated with its Phase III clinical trial in the area of COVID-19 associated ARDS. ARDS is a condition in which lung injury causes fluid to leak into the spaces between th … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Subscribe Digital + Home Delivery Digital Access Globe2Go The New York Times Globe Email … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Jump to footer navigation © Copyright 2026 The Globe and Mail Inc. All rights reserved. 3
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
JPPCLE - jjpcle.org JPPCLE 2026 SEMINAR 2026 Written Materials About Registration Sponsorship FAQ Register Here 2026 Seminar Agenda Earn 6.5 NY/ NJ/CT (6.0 PA) CLE credits including 1 Ethics Featured Speakers Program Opening Welcome Remarks by 2026 JPPCLE Chair 8:55 - 9:00 AM EST Weihong Hsing, Ice Miller Featured Morning Speaker 9:00 - 9:30 AM EST Hon. Kalyan Deshpande ​ Chief Judge for the Patent Trial and Appeal Board (PTAB), USPTO Panel 1 USPTO & PTAB Practice 9:30 - 10:30 AM EST Moderator: Stephen E. Murray , Panitch Schwarze Belisario &a … PM Prosecution Laches; raised the standard for proving prosecution laches if an application has published: Speaker: Excylyn Hardin-Smith, Fish & Richardson Google, LLC v. Sonos, Inc. (Fed. Cir., Aug. 28, 2025) 1:30 - 1:40 PM Infringement; Reverse Doctrine of Equivalents: Speaker: Robert L. Hails Jr., BakerHostetler Steuben Foods, Inc. v. Shibuya Hoppmann Corp. (Fed. Cir., Jan. 24, 2025) ​ ​1:40 - 1:50 PM Equitable Estoppel; b … :50 PM EST Moderator: Jenny Lee , Haug Partners 3:50 - 4:00 PM Award of attorney’s fees for frivolous suit of patent infringement: Speaker: Matthew Grillo, Pillsbury Winthrop Shaw Pittman EscapeX IP, LLC v. Google LLC, No. 24-1201 (Fed. Cir., Nov. 25, 2025) Future Link Systems, LLC v. Realtek Semiconductor Corp. (Fed. Cir., Sept. 9, 2025) 4:00 - 4:10 PM Cautionary tales for use of AI in litigation: ​ Speaker: Jordan Garner,  
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
March 2026 - The IPKat The IPKat Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate! The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here! The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel. SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor). InternKats: Wissam Bentazar, Simone Lore … Legal Business , April 2023. * PermaKat Eleonora Rosati received the 2022 Adepi Award . * PermaKat Eleonora Rosati was listed as one of World Intellectual Property Review’s “Influential Women in IP” in 2020. * PermaKat Eleonora Rosati was listed as one of Managing Intellectual Property magazine’s “Fifty Most Influential People” in 2018. * IPKat founder and Blogmeister Emeritus Jeremy Phillips was listed as one of Managing Intellectual Prope … listed in the 2010 ABA Journal Blawg 100 . * Court Reporter Top Copyright Blog award winner, November 2010. * Number 1 in the 2010 Top Copyright Blog list compiled by the Copyright Litigation Blog, July 2010. * Selected by the United States Library of Congress for inclusion in its historic collections of Internet materials related to Legal Blawgs as of 2010. * Top Patent Blog poll 2009: 3rd out of 50 (“Favourite Patent Blog”) and 2nd out of 50 (“Most-read&# … similar technologies. For all third-party content, the relevant licensing terms apply. | Design Created By SoraTemplates | Distributed By Gooyaabi Templates Powered by Blogger .
%PDF-1.4 %���� 1 0 obj /Producer /CreationDate (D:20221005224634-04'00') /ModDate (D:20221005224634-04'00') /Author /Title >> endobj 4 0 obj > stream x��WmSG ��_q wg����no�f�)$�P��ÄN'M̄�@�L��G�=��t����Ϸڕ I�����^7���Ɨ�+���)*�3E�E�Biۢ� 1�� z�AT{��m��Y?��ĥSo��t�QO4����0�����!(B,�*� 1�G�"R��P&�ʯ�x�yk��z� �:�Q����l3���5L;����_�F��M��Q R�ݚo�Ț���F��-j-�5/�z�fi �Z[�3��m8Jx����s���F��Ø��^��o ��!k$�1E�D��yAv����t J�H+�4Ċ�ybQ'��0a�D��!�W��y;M���$��&��$��� ���S(aP&�2���d��ole�] �j�0� P�����,C�1�~.mbȚv�oa ��~V����q.�|@�#] ���{��%�Сvt��W y, ,�x��6�C����ج�] \�+�� �R�W��7)��P�ۖzx�
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.7 %���� 1964 0 obj > endobj 1983 0 obj >/Filter/FlateDecode/ID[ ]/Index[1964 29]/Info 1963 0 R/Length 95/Prev 10510225/Root 1965 0 R/Size 1993/Type/XRef/W[1 2 1]>>stream h�bbd``b�:$���^ �� $�� �.qĝbe �B ��"^�$XA�E � $4� ���o ������n d100 ���� `7�7 endstream endobj startxref 0 %%EOF 1992 0 obj >stream h��V�SSg�n�@H ��D�$4���,�!����:��8��- C 1F�5 nx��n[ ����O���eu�vf�t�n��+���t��nH����d�9���������`��=������cD�$�,��#���ʨ�Z{ufdPkh$�VҌ���m ��z����������Ў s��0'���:��BR���� �nm�`� G(�4Q̩�˂m9=\�h[w�j�rr��=��S\y��'���� o��̨_�r�f,����9f#�Ul�n�M����� … �ed�3 !��! �&�]J i��R'q���Ŋ����o%$s�~ 0�M'� endstream endobj 1981 0 obj >stream application/pdf WHO-AFRO_White_EN_RGB 2022-10-24T09:17:10Z 2022-10-24T09:17:10Z 2022-10-24T09:17:10Z Adobe Illustrator 26.5 (Macintosh) uuid:3545cb22-0ca8-8e49-b22f-1ba5ac4364a1 xmp.did:da4277b6-d087-4d54-8ba9-f5e3790e6ba6 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:bff9c51e-873a-c64d-8d6f-e725dab8e06e xmp.did:c0b8aeb8-4114-403b-8e3f-03ec323a8d37 uuid:5D20892493BFDB11914A8590D31508C8 proo … e 2021-11-30T15:54:08-05:00 Adobe Illustrator 24.3 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:c00c75f1-5200-4b7c-b69c-9e30d176d126 2022-10-24T09:16:05Z Adobe Illustrator 26.5 (Macintosh) / saved xmp.iid:da4277b6-d087-4d54-8ba9-f5e3790e6ba6 2022-10-24T09:17:10Z Adobe Illustrator 26.5 (Macintosh) / Print AIRobin Document False False 1 4.339795 2 … ,3:DI����C/t���pc�Nv�[�]w6��?���`ǹ�(��1� endstream endobj 6 0 obj >stream application/pdf WHO-AFRO_Black_EN_CMYK 2022-10-24T09:17:36Z 2022-10-24T09:17:36Z 2022-10-24T09:17:36Z Adobe Illustrator 26.5 (Macintosh) uuid:90bb67a1-66b5-d744-b30a-649d08d3be36 xmp.did:4baaa2a9-32f6-49d9-807d-0794190dccb2 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:f9676a12-c718-6b46-8b65-88a206f6a8b6 xmp.did:b975226f-0416-4a4c-895a-b807935ae0f6 uuid:5D20892493BFDB11914A8590D31508C8 def … e 2021-11-30T15:54:08-05:00 Adobe Illustrator 24.3 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:c00c75f1-5200-4b7c-b69c-9e30d176d126 2022-10-24T09:16:05Z Adobe Illustrator 26.5 (Macintosh) / saved xmp.iid:4baaa2a9-3
About « Welcome to the ReSTEM Institute Home About History Relevant Resources Mission & Goals People Affiliation Partners Contact News-Events Research Research Projects Development Development Projects Outreach Outreach Programs Evaluation Evaluation Projects Links Welcome to the ReSTEM Institute Reimagining & Researching STEM Education Search Search Twitter Welcome to the ReSTEM Institute Home » About About The ReSTEM Institute is a research center based at the University of Missouri College of Education. ReSTEM catalyzes and studies innovation and reform of K-12 STEM educ
%PDF-1.6 %���� 7013 0 obj > endobj 7030 0 obj >/Filter/FlateDecode/ID[ ]/Index[7013 25]/Info 7012 0 R/Length 97/Prev 1638160/Root 7014 0 R/Size 7038/Type/XRef/W[1 3 1]>>stream h�bbd```b``M��/�d�dY"���d3�4.�"b Rc�db�R��"�@��H c�H�8D���ߎ� L� �_@"@p����� `�r6 endstream endobj startxref 0 %%EOF 7037 0 obj >stream h��TILa~����t�*�M ��#ƈ�4RS��B1��\�@b�S�PMH�I9 �7�QS�=I%r 1���`Ћ���L( 0 ��cBJ*LE >/Metadata 239 0 R/OCProperties >/OCGs[7031 0 R]>>/Outlines 274 0 R/PageLayout/SinglePage/Pages 6999 0 R/StructTreeRoot 383 0 R/Type/Catalog>> endobj 7015 0 obj >/ExtGState >/ … :bd20fa3c-5d92-4794-b9a6-513636d45311 uuid:337a9c06-0c71-4c8b-9e76-0fe2305d2e2a application/pdf Cell, Gene, & RNA Therapy Landscape Nguyen-Jatkoe, Ly Adobe PDF Library 24.5.96 0x010100985091CA06F37C4FA8620137FD09A28E true 2021-10-21T20:39:20Z Privileged e1b4a6d7-967f-4d55-9d13-d94940dabb24 2567d566-604c-408a-8a60-55d0dc9d9d6b 5b676819-73a2-4186-881c-90f78c7294ca 0 endstream endobj 240 0 obj >stream hޜ��N1 �_�o���?K�k(iN':Dq+D����'�qVB N{�̮�/N��fF�J�b]���#$܍�X7��t�(�n
%PDF-1.4 %���� 1533 0 obj > endobj xref 1533 58 0000000016 00000 n 0000002652 00000 n 0000002803 00000 n 0000003505 00000 n 0000003839 00000 n 0000004185 00000 n 0000004805 00000 n 0000005081 00000 n 0000005196 00000 n 0000005309 00000 n 0000005360 00000 n 0000005411 00000 n 0000005462 00000 n 0000005513 00000 n 0000005564 00000 n 0000005757 00000 n 0000006327 00000 n 0000006579 00000 n 0000007852 00000 n 0000008420 00000 n 0000008701 00000 n 0000009307 00000 n 0000010890 00000 n 0000012764 00000 n 0000014600 00000 n 0000016450 00000 n 0000018195 00000 n 0000020032 00000 n 0000022128 00000 n 0 … MMMLLLKKKJJJIIIHHHGGGFFFEEEDDDCCCBBBAAA@@@???>>>=== > endobj 1573 0 obj >stream application/postscript CrisisCenter Logo FINAL LG Adobe Illustrator CS3 2008-05-21T16:25:16-07:00 2008-05-21T16:25:16-07:00 2008-05-21T16:25:16-07:00 256 80 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f … ONE Process Blue C SPOT 100.000000 CMYK 100.000000 10.000000 0.000000 10.000000 application/postscript proof:pdf xmp.did:F77F1174072068118F62DF684B8C8BC1 xmp.iid:F77F1174072068118F62DF684B8C8BC1 xmp.did:FC7F117407206811994CAD6A22F7EB11 xmp.iid:FC7F117407206811994CAD6A22F7EB11 xmp.did:FC7F117407206811994CAD6A22F7EB11 xmp.did:FC7F117407206811994CAD6A22F7EB11 proof:pdf saved xmp.iid:FC7F117407206811994CAD6A22F7EB11 2009-10-07T10:53:18-04:00 Adobe Illustrator CS4 / converted from … 4CAD6A22F7EB11 2009-10-07T10:53:18-04:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:F77F1174072068118F62DF684B8C8BC1 2009-10-09T08:18:24-04:00 Adobe Illustrator CS4 / endstream endobj 56 0 obj [/ICCBased 1564 0 R] endobj 57 0 obj >stream 50 0, 0 32, 22 64, 56 128, 128 192, 196 255, 255 Alex McKnight © Alex McKnight 2011 Wendy board c … ndobj 145 0 obj >stream ����ph�@6沮ݙ�ٍ��f^�3( endstream endobj 146 0 obj >stream application/postscript CrisisCenter Logo FINAL LG Adobe Illustrator CS3 2008-05-21T16:23:19-07:00 2008-05-21T16:23:40-07:00 2008-05-21T16:23:40-07:00 256 80 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlA
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��[[o�F~7��0��"ϝd�e;Ѣq���[�A+˶EJ%����=� )_ȩ(iTlS�g�m�exr�,��q�?9-���ir�~=.��v2��urr=z��G�t1?����O}���'�^�������G� ��K�s�MsŖ�㣟����Gg�㣓Kɤ�°�����,U\(�Rc�ul���p�����=�QV }8>��Ò����G�� m����ŧ>; �lQ�/�^.��#U .� �՚�Yŵ14L]9(���B(Fpمs;SR�Ug�F"���N�Q|���s&���~K�r�;�R��Nc��r���t�m�-��ΗD��)�¹b�g&�����:H�^�� �UMcs�%s����O��� �wVßhJ+ �\�]�u�J��#_E&k �nb�ڒ�I�s�Z��(H … 6 2021-08-09T13:56:47-04:00 2021-09-14T13:36:38-04:00 2021-09-14T13:36:38-04:00 application/pdf Scott Olson uuid:a609dd70-382f-f980-ff3a-71c39d66cc11 uuid:9e60a12f-5872-8c88-7d07-86ccc9e0cdf3 endstream endobj xref 1 1 0000564616 00000 n 3 1 0000564779 00000 n 20 1 0000565140 00000 n 22 1 0000565472 00000 n 29 1 0000565844 00000 n 31 1 0000566206 00000 n 33 1 0000566568 00000 n 35 1 0000566920 00000 n 37 1 0000567282 00000 n 39 1 0000567634 00000 n 41 1 0000567976 00000 n 43 1 … 6 2021-08-09T13:56:47-04:00 2021-09-14T13:36:58-04:00 2021-09-14T13:36:58-04:00 application/pdf Scott Olson uuid:a609dd70-382f-f980-ff3a-71c39d66cc11 uuid:9e60a12f-5872-8c88-7d07-86ccc9e0cdf3 endstream endobj 1928 0 obj >>> endobj 1929 0 obj >stream / RESTEM 1006 Restem v. Amit Patel endstream endobj 1930 0 obj /ON endobj 1931 0 obj > endobj 1932 0 obj > endobj 1933 0 obj /ON endobj 1934 0 obj > endobj 1935 0 obj /ON endobj 1936 0 obj > endobj 1937 0 obj /FG endobj 1938 0 obj
Quality Assurance, Regulatory Compliance, and Documentation Specialist - Restem Group Inc. / thebiobox LLC | BeBee Skip to main content Jobs People Services Resume Builder Blog United States Jobs Technical Writer Quality Assurance, Regulatory Compliance, and Documentation Specialist Back Quality Assurance, Regulatory Compliance, and Documentation Specialist Technology Restem Group Inc. / thebiobox LLC Corona , United States From $5,000 /month 2 weeks ago Until 8/6/2026 Full time On-site Save Apply now Adapt my CV to this job Job description Job Overview The QA and Regulatory Compliance and Doc … nagement supplier-management vendor-management-program Interested in this role? Apply Adapt my CV to this job Connecting talent with opportunities. Jobs, services, and freelance in one place. Navigation Search jobs People Companies Services Talent Salary Guide Job Market Report Industries Job Market by City Skills Professions Job Market Trends Remote Jobs Blog Employer resources BeBee For job seekers For employers Offer your services Find a professional Bloggers About How It
Restive Ventures - VC Firm Profile - Gaebler.com Venture Capital Database Search Menu Get Started Startup Advice Business Ideas Buy a Business Business Plans Form a Legal Entity Startup Resources Freelancing Web Publishing Entrepreneur Interviews Business Demographics Find More Resources Promotion Marketing Advertising Public Relations Find More Resources Sales & Service How to Sell Customer Service Find More Resources Operations Business Strategy Human Resources Leadership Intellectual Property Business Advisors Legal Resources Running a Business Operations Management Business Security Bu … ler Griffin Funds No fund closings have been recorded for this company. Portfolio Companies Restive Ventures has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know. Tech Company Location AiPrise Santa Clara, CA 95051 USA BlueQuibit San Francisco, CA Undisclosed USA Brico San Francisco, CA Undisclosed USA Diesta Eastbourne, BN21 4RU Unite
Federal Circuit Affirms Stem Cell Product-by-Process Claims: Lessons in Claim Construction and Inherency from Restem LLV v. Jadi Cell LLC - Insights - Proskauer Rose LLP Proskauer Services Practices Industries Market Solutions Corporate/Transactional Discover Corporate/Transactional Broker-Dealer Capital Markets Digital Infrastructure Environmental Global Finance Health Care Regulatory Compliance Investment Management Latin America Mergers & Acquisitions Privacy & Cybersecurity Private Credit Private Equity Transactions Real Estate Restructuring Technology & IP Transactions Labor &
false FY 0000748592 0000748592 2025-01-01 2025-12-31 0000748592 ERNA:CommonStock0005ParValueMember 2025-01-01 2025-12-31 0000748592 ERNA:CommonStockPurchaseWarrantsMember 2025-01-01 2025-12-31 0000748592 2025-06-30 0000748592 2026-03-12 0000748592 2024-01-01 2024-12-31 0000748592 2025-10-01 2025-12-31 0000748592 2025-12-31 0000748592 2024-12-31 0000748592 us-gaap:RelatedPartyMember 2025-12-31 0000748592 us-gaap:RelatedPartyMember 2024-12-31 0000748592 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0000748592 us-gaap:CommonStockMember 2024-12-31 0000748592 us-gaap:A … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth compa … s and Industry   ● We will require substantial additional capital to fund our operations, and if we fail to obtain the necessary financing, we may not be able to continue as a going concern.       ● We have incurred significant losses since our inception and expect to continue to incur losses for the foreseeable future, which, together with our limited financial resources and substantial capital requirements, make it difficult to assess our pro … applications or provisional patent applications, and 4 pre-nationalization PCT application. Patent protection for the iMSC technology platform includes:   Family Number and Title   United States or Foreign Jurisdiction   Earliest Effective Date of Patent Application FAB-001: “Methods and Products for Transfecting Cells”   Granted:   US (Nos. 10829738, 10982229, 11692203, 10472611, 11466293, 10662410, 12227757; 12391961);   EP (No. 27 … ts have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the U.S. and the European Union are granted a term of 20 years from the earliest effective
RESTEM LLC - Finance and Accounting | The Org Platform Enrich Pricing Log in Sign up RESTEM LLC Teams Finance and Accounting Unverified Finance and Accounting 2 people · 0 jobs This department manages the financial operations and reporting functions of the organization. People ( 2 ) Maxime Maheux Director of Technical Accounting and Financial Reporting NC Nelson Cabatuan Chief Financial Officer Jobs ( 0 ) No jobs in this team Other teams View all teams Cell Therapy Operations 2 people · 0 jobs TP Executive Leadership 2 people · 0 jobs DP Company About Contact Blog Business Solutions Trust Pr
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
FDA approves COVID-19 trial after successful emergency use of umbilical stem cells from RESTEM Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Phot … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Restem Incorporated - Nonprofit Explorer - ProPublica Nonprofit Explorer Wisconsin Restem Incorporated Hartland, WI Tax-exempt since Feb. 2022 EIN: 87-3881727 Organization summary Type of Nonprofit Designated as a 501(c)(3) Organizations for any of the following purposes: religious, educational, charitable, scientific, literary, testing for public safety, fostering national or international amateur sports competition (as long as it doesn't provide athletic facilities or equipment), or the prevention of cruelty to children or animals. Category : Educational Institutions and Related Activiti … ildren or animals. Category : Educational Institutions and Related Activities / Fund Raising and/or Fund Distribution (NTEE) Donations to this organization are tax deductible. No Financial Data Available Nonprofit Explorer has no Form 990 data for Restem Incorporated . This website only contains IRS digitized Form 990 data for filings processed in 2012 and later. Only organizations which filed a full Form 990, Form 990PF, or Form 990EZ are included. Small organizations (less … copies of audits nonprofit organizations that spent $750,000 or more in Federal grant money in a single fiscal year since 2016. These audits are copied from the Federal Audit Clearinghouse. Which Organizations Are Here? Every organization that has been recognized as tax exempt by the IRS has to file Form 990 every year, unless they make less than $200,000 in revenue and have less than $500,000 in assets, in which case they have to file form 990-EZ. Organizations making less t … cific audits for nonprofit organizations that spent $750,000 or more in Federal grant money in a single fiscal year. Available for fiscal year 2015 and later. API The data powering this website is available programmatically, via an API. Read the API documentation » See an issue with the data? Contact Us About Nonprofit Explorer Nonprofit Explorer Browse millions of annual returns filed by tax-exempt organizations with ProPublica’s Nonprofit Explorer. See details like executiv
Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell) - The IPKat The IPKat Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate! The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here! The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel. SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Ro … Legal Business , April 2023. * PermaKat Eleonora Rosati received the 2022 Adepi Award . * PermaKat Eleonora Rosati was listed as one of World Intellectual Property Review’s “Influential Women in IP” in 2020. * PermaKat Eleonora Rosati was listed as one of Managing Intellectual Property magazine’s “Fifty Most Influential People” in 2018. * IPKat founder and Blogmeister Emeritus Jeremy Phillips was listed as one of Managing Intellectual Prope … listed in the 2010 ABA Journal Blawg 100 . * Court Reporter Top Copyright Blog award winner, November 2010. * Number 1 in the 2010 Top Copyright Blog list compiled by the Copyright Litigation Blog, July 2010. * Selected by the United States Library of Congress for inclusion in its historic collections of Internet materials related to Legal Blawgs as of 2010. * Top Patent Blog poll 2009: 3rd out of 50 (“Favourite Patent Blog”) and 2nd out of 50 (“Most-read&# … similar technologies. For all third-party content, the relevant licensing terms apply. | Design Created By SoraTemplates | Distributed By Gooyaabi Templates Powered by Blogger .
RESTEM to Present at BIO International Convention | The National Skip to main content June 27, 2026 Volume XVI, Number 178 Legal Analysis. Expertly Written. Quickly Found. Login Publish / Advertise Publish Advertise Publishing Firms NLR Newsletters Contact Us Terms of Use Privacy Policy About Contact Us NLR Team Publishing Firms NLR Newsletters NLR Thought Leadership Awards 2018 2019 2020 2021 2022 Terms of Use Privacy Policy Quick Links Type of Law Antitrust Law Artificial Intelligence Law News Bankruptcy & Restructuring Biotech, Food & Drug Business of Law Construction & Real Est
RESTEM Provides Corporate Update and Announces Strategic --> Accessibility: Skip TopNav RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026 January 08, 2026 08:00 ET | Source: Restem Restem MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today provided a corporate update and announced its strategic priorities for 2026. “We had a remarkable 2025, where we made significant progress across our pipeline of advanced cell therape
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Publications About Us Our Science Programs Restem-L rESTEM-x a NK Program Our Pipeline Clinical Trials Idiopathic Inflammatory Myopathy Rheumatoid Arthritis Facioscapulohumeral Muscular Dystrophy Culture Contact Us Investors & Media Press Releases Publications Corporate Presentation & EVENTS Investors & Media Publications Press Releases Publications Corporate Presentation & eVENTS Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recipients: Results of the uSTOP LVAD BLEED pilot study Mustafa M. Ahmed MD a , Lauren E. Meece DNP a ,
Restem-L - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 03 Feb 2026 Restem-L Last update 03 Feb 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Mesenchymal stem cell therapy Synonyms ULSC (Restem), Umbilical cord derived mesenchymal stem cell therapy (RESTEM), Umbilical cord lining stem cells (ULSC) Target - Action - Mechanism Cell replacements Therapeutic Areas Immune System Diseases Nervous System Diseases Skin and Musculo … y inflammatory factors in related muscle inflammatory indications, and chose to fund this study after reviewing numerous other technologies and platforms. The initiation of this trial inches us closer to bringing hope to the up to 1 million patients estimated to suffer from FSHD worldwide.” The Phase 1/2a study (NCT07086521) is a double-blind, randomized, dose-repeating, placebo-controlled, cross over study to assess the safety and preliminary efficacy of allogeneic UMPCs on … could also benefit from an accelerated approval pathway, priority reviews, and rolling submissions, allowing the Company to bring this potentially life-changing treatment to IIM patients sooner.Initiate Phase 2 clinical trial in rheumatoid arthritis patients who are refractory to standard of care in the second half of 2025.Advance aNK cell program to develop and utilize allogeneic aNK cells and aNK-derived exosomes, aiming to broaden their application for patients with age-a
Pipeline About Us Our Science Programs Restem-L rESTEM-x a NK Program Our Pipeline Clinical Trials Idiopathic Inflammatory Myopathy Rheumatoid Arthritis Facioscapulohumeral Muscular Dystrophy Culture Contact Us Investors & Media Press Releases Publications Corporate Presentation & EVENTS Our Pipeline Novel cell therapeutics for diseases with high unmet needs. Restem is building a robust pipeline primarily focused on autoimmune diseases as well as aging and cell senescence. Clinical Trials Rheumatoid Arthritis Learn more Facioscapulohumeral Muscular Dystrophy Learn more Idiopathic Inflamm
Science About Us Our Science Programs Restem-L rESTEM-x a NK Program Our Pipeline Clinical Trials Idiopathic Inflammatory Myopathy Rheumatoid Arthritis Facioscapulohumeral Muscular Dystrophy Culture Contact Us Investors & Media Press Releases Publications Corporate Presentation & EVENTS Our Science Programs We are developing a a new form of medicines to improve patient’s lives RESTEM’S ground-breaking cell-based therapeutics can target difficult to treat autoimmune as well as age-related diseases. RESTEM is developing, Restem-L, an off-the-shelf and allogeneic cell-based therapeutics to
RESTEM and JAR of Hope Foundation Announce Strategic Partnership and Clinical Trial Launch of Next-Generation Cell Therapy for Patients with Duchenne Muscular Dystrophy Accessibility Statement Skip Navigation Why PRWeb How It Works Who Uses It Pricing Login GDPR Create a Free Account News Resources Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases Multimedia Gallery All M … Overview RESTEM has received FDA authorization for its Investigational New Drug Application (IND) entitled "A Phase I, randomized, double-blind, placebo-controlled cross over study to assess the safety, tolerability, and preliminary efficacy of Umbilical Cord Lining stem cells (ULSC) in pediatric patients with Duchenne Muscular Dystrophy (DMD)". The trial is planned to enroll 12 patients. In previous clinical trials in other indications, RESTEM's ULSCs have demonstrated an ex … a Free Account Log in Contact Us Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Online Member Center ProfNet Cision Distribution Helpline 888-776-0942 Legal Site Map RSS Cookie Settings Copyright © 2025 Cision US Inc. --> -->
Home About Us Our Science Programs Restem-L rESTEM-x a NK Program Our Pipeline Clinical Trials Idiopathic Inflammatory Myopathy Rheumatoid Arthritis Facioscapulohumeral Muscular Dystrophy Culture Contact Us Investors & Media Press Releases Publications Corporate Presentation & EVENTS Restoring Immunity. advancing cell therapy. Modulating Immune Response Through Advanced Cell Therapeutics We are advancing the future of immune health by harnessing advanced cell-based therapeutics to treat inflammatory-driven diseases. By tapping into the body’s natural ability to restore balance, we’re tr
Polishing briar with micromesh sanding pads | rebornpipes rebornpipes reclaiming old and worn estate pipes Menu Skip to content Home About reborn pipes Contact Pipe Refurbishing Links for Quick Reference Q & A Forum Thanks To Contributors WELCOME TO THE REBORNPIPES STORE PIPE RESTORATION GRAB BAGS & TOOLS PIPES MADE BY AMERICAN (US) PIPEMAKERS AND PIPE MAKING COMPANIES PIPES MADE BY CANADIAN PIPEMAKERS PIPES MADE BY BRITISH PIPEMAKERS PIPES MADE BY DANISH PIPEMAKING COMPANIES PIPES BY IRISH PIPEMAKING COMPANIES PIPES BY FRENCH PIPEMAKING&nbs
Restem_LLC_v_Neuvian_LLC_et_al__flsdce-25-20229__0001.0.pdf PacerMonitor A Fitch Solutions Service Features Plans & Pricing About Home Features Pricing Getting Started About Us Start Free Trial Sign In Admin Login × START YOUR 14-DAY FREE TRIAL Confidential, secure access. Switch plans or cancel any time. We have this document in our database and it is free with your trial access. PLUS For small businesses and individuals USD 49 monthly ✔ Documents 15¢ / page ✔ 5 free custom alerts ✔ Full database access ✔ Free basic searching START FREE TRIAL FREE FOR 14 … IAL FREE FOR 14 DAYS * Monthly subscription waived during trial. Usage fees may apply. Privacy Policy • Cookie Policy • Terms • About PacerMonitor, LLC © 2026.
RESTEM LLC | The Org Platform Enrich Pricing Log in Sign up RESTEM LLC 1 follower RESTEM, LLC is a clinical-stage biotech firm dedicated to the development and research of cell-based therapeutics to treat degenerative disorders. RESTEM has multiple ongoing clinical trials demonstrating the benefits umbilical cord lining stem cells. Industries Biotechnology , Clinical Trials + 1 Headquarters Corona, United States Employees 1-10 Links Org chart Teams Offices Positions ( 8 ) Unverified Org chart DP David Pyrce CEO 4 DP David Pyrce Collapse Brian Pla Chief Commercial Officer (cco) 0 NC Nelson Ca
RESTEM Launches NK Cell Therapy Program with Publication of Results from Clinical Study of NK Cell Therapy Targeting Senescence and Age-Associated Disorders Accessibility Statement Skip Navigation Why PRWeb How It Works Who Uses It Pricing Login GDPR Create a Free Account News Resources Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases Multimedia Gallery All Multimedia Al … a Free Account Log in Contact Us Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Online Member Center ProfNet Cision Distribution Helpline 888-776-0942 Legal Site Map RSS Cookie Settings Copyright © 2025 Cision US Inc. --> -->
David Pyrce - CEO at RESTEM LLC | The Org Platform Enrich Pricing Log in Sign up RESTEM LLC David Pyrce Unverified DP David Pyrce CEO Contact No bio yet Org chart View org chart View position Brian Pla Chief Commercial Officer (cco) NC Nelson Cabatuan Chief Financial Officer Teams View all teams Executive Leadership 2 people, 0 jobs Offices View all offices This person is not in any offices Related people Jarand Rystad Rystad Energy Gianni Furino NOWDiagnostics Tarvo Topolev RebelRoam Randall J. Krause Eplace Sathish Kumar BigilToks Xavier Lernould Novity View more Company About Contact Blog
Andrés Isaias Profile | fundable. fundable. DATA PLATFORM Dashboard Companies People Investment Firms Angels & Partners COLLECTIONS Lists Saved Searches Hiring Lists WORKFLOWS Deal Alerts Integrations API + Credits Toggle Sidebar Overview Highlights Firm Deals Andrés Isaias Investor at Restem Group Investments 1 Lead Investments 1 Miami, Florida, United States , US Highlights Focus Areas Biotechnology Oncology Pharmaceutical Firms Invested Under Restem Group Recent Investments Firm Investments Filters Sort
Andres Isaias Andres Isaias Home About Me Get In Touch Andres Isaias - Experienced Leader of Restem - a Miami-based Cell Therapeutics Life Science Company Andres Isaias has served as the CEO of Restem Group, Inc., in Miami since 2018. At the company focused on cell therapeutics, his responsibilities involve oversight of all Restem operations, including the management of organizational performance and alignment with short- and long-term strategic goals. Mr. Isaias also functions as the company’s ambassador, with a mission of strengthening the Restem brand, bringing cell therapeutic produc
%PDF-1.7 %���� 1 0 obj >/Metadata 1254 0 R/ViewerPreferences 1255 0 R>> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 5 0 R/Group >/Tabs/S/StructParents 0>> endobj 5 0 obj > stream x��]�r�6��w�߁�b&���K��ʖ�q�(kEIV9�=�tbI^Y��y�}�}��n�1�a���P�I�Xaȯ� �y�������W7٣����m����{���A��_W� VZMV+�5�ήW����Yvy�^[�U��m��dU���1�髋���^�|����W���e_�eG�_�z�������߲G�3{�J好�*�ܴ�:�r:� �[��Y0�Q���n�.�~k�\�]ao�������^����������R�p㮰�杮��T���w�%Lm��YՖyoa/�[���q�TEޮ�Ym}k�)5�T��\�&��G�V�_��λ:;~s���
Restem - 2026 Company Profile, Team & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates and
Patenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell) - evolve PHARMACEUTICAL IP Our Offering Fractional in-house Start-ups Established pharma International IP counsel Investors Due diligence Evolve AI Fractional in-house Sectors Pharmaceuticals Biotechnology Biologics Cell & gene therapies AI drug discovery Chemistry Evolve Insights Articles Events & Webinars Subscribe About us Our team Join us Contact us Our Offering Fractional in-house Start-ups Established pharma International IP counsel Investors Due diligence Evolve AI Fract
RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025 January 13, 2025 | 3 min read Twitter LinkedIn Facebook Email Print MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed … could also benefit from an accelerated approval pathway, priority reviews, and rolling submissions, allowing the Company to bring this potentially life-changing treatment to IIM patients sooner. Initiate Phase 2 clinical trial in rheumatoid arthritis patients who are refractory to standard of care in the second half of 2025. Advance aNK cell program to develop and utilize allogeneic aNK cells and aNK-derived exosomes, aiming to broaden their application for patients with age … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L in Facioscapulohumeral Muscular Dystrophy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L in Facioscapulohumeral Muscular Dystrophy December 8, 2025 | 4 min read Twitter LinkedIn Facebook Email Print − First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor … y inflammatory factors in related muscle inflammatory indications, and chose to fund this study after reviewing numerous other technologies and platforms. The initiation of this trial inches us closer to bringing hope to the up to 1 million patients estimated to suffer from FSHD worldwide.” The Phase 1/2a study ( NCT07086521 ) is a double-blind, randomized, dose-repeating, placebo-controlled, cross over study to assess the safety and preliminary efficacy of allogeneic UMPCs o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference April 2, 2025 | 1 min read Twitter LinkedIn Facebook Email Print MIAMI, April 01, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to m … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
RESTEM to Present at BIO Investment & Growth Summit 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rele … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM to Present at BIO Investment & Growth Summit 2026 February 23, 2026 | 1 min read Twitter LinkedIn Facebook Email Print MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the im … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
RESTEM to Present at BIO International Convention - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All Ne … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM to Present at BIO International Convention June 18, 2026 | 1 min read Twitter LinkedIn Facebook Email Print MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, to … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy February 4, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful effica … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica … potential to benefit from accelerated approval pathways, priority reviews, and rolling submissions, potentially expediting its availability to patients with IIM. Regulatory Support and Manufacturing Expansion RESTEM Search company has received IND approval from the FDA for the Phase 2/3 clinical study in IIM, as well as a Phase 2 study in rheumatoid arthritis Search disease . The FDA has also granted Fast Track Designation and Orphan Drug Designation to Restem-L Search drug
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Andres Isaias - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailing l … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.5 %� 45 0 obj > stream x�mTˎ�0��+�$���$0�� ����� �a#A%��߯����jD�岻��f��c;Z����̫����MfG��}� q�]/��ޭ�mޯ�o⣩����0Z���^�x]f�kn{��E+{*ʧy�pg�6;5�P���V��pH8$h��mڢ*߄z�R:")���3�q��X�ysO'H�)-�"��}������[��˺ s ��3 4�{��p�Y�d�r���K�+���� a }����ѫ�W���{ Fvm734�4�����A����G��c ڤ�_86endstream endobj 46 0 obj > stream x�mU�n�0���E��"��y$U�6�ɢ5�h�)8 �"�,���c\W��s�/.7?��3��oz��(yѧ�2�z� v������Aw�G���=y �z���Vm�Mמ�MW\=j�_I����*�Cn_����f� ����& 1y�+���S�w�$���F�5�? �S4��!�1�����!r3Ҵ����>�Za�� �?�ɻ�=���ñK��}:�j=�w �(]�UU�#�5�d� k� u�ѥ�y �e���*��x12+��Sx��,���0 … #*ЙX #\AK����}a! �"|�%(R�{kxe~�� +�z疰�w(��S�h2̦��O��B� ��W8�:����ϲ��&�p�_�rFp�/���AyJ� d�z������ֈECj�+V�A�F��µ= �vҠH�PS�";:�m -U�~d g��@�f�������]�y'�1�Mʛ/�e[��oe�[ ����#� g8�y~LbJ�H���տ�㠐f�=��Zc�~oeI��sk3`�\'�.�t�`�N9=�bVL�XqzM9��`��>b��&;�5S�kN�V�K\�0������ �Z�j^\�~d}_�=�g��j�� ��~{B�}�/I�b��Hm���z,�z�q2���ѢC� ԋǛ����L�9�a1p�R�thpr���#X.��gB2�[8jܶ���i ��Os���_CЇ�S�Z��0&:�t�� N~9��XQӳ�pP�[,���{�6nnd���:�0 ��� �����s1IZ���1����
%PDF-1.7 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj [ 6 0 R 7 0 R 8 0 R 9 0 R 10 0 R ] endobj 6 0 obj >stream x�+��| endstream endobj 7 0 obj >stream x�+��| endstream endobj 8 0 obj >stream x�+T030�34S0Bs =0+9WA�-"�P�%_!� ��� endstream endobj 9 0 obj >stream x�}W]oG}�W�R�H�t�g�ok��[a�˒�Q_h ��RL�6����홙5�Βʒ��3wν��3����ҼY�} �4�k@����{��z3`�C���ip[_��S�(��J�a�4�(�rX�a}�~��]?o&���9p�z;Z���q���x ¹ ª� ���_F����yN��"����Dd:>|>��H!%1���H摇m�u�]p�(�p��O��eV��PI�� �N�̄D��c��!B]k����&jNd��@0��l 7��.͒���\u\A���ssJ[ *j��Θ �IS��U,���ur�ĸ �pa�
--> APsA-national-conference top of page Log In Home About Us FAQ Current Projects Wall of Donors Donate Contact 2026 annual APsA conference San Fran URiM medical students & residency Kids looking in the mirror Help IMGs obtain residencies in USA More Use tab to navigate through the menu items. Help individuals attend the 2026 National meeting of the American Psychoanalytic Association In 2015, my first APsA meeting changed my life forever. However, as many of you know by now, for many individuals, the annual in-person meetings can be cost-prohibitive. In partnership with
reSTEM-website/research101.html at master · YSJ-Production/reSTEM-website · GitHub Skip to content Navigation Menu Toggle navigation Sign in Appearance settings Platform AI CODE CREATION GitHub Copilot Write better code with AI GitHub Copilot app Direct agents from issue to merge MCP Registry New Integrate external tools DEVELOPER WORKFLOWS Actions Automate any workflow Codespaces Instant dev environments Issues Plan and track work Code Review Manage code changes APPLICATION SECURITY GitHub Advanced Security Find and fix vulnerabilities Code security Secure your code as you build Secret protec … Trust center Partners View all resources Open Source COMMUNITY GitHub Sponsors Fund open source developers PROGRAMS Security Lab Maintainer Community Accelerator GitHub Stars Archive Program REPOSITORIES Topics Trending Collections Enterprise ENTERPRISE SOLUTIONS Enterprise platform AI-powered developer platform AVAILABLE ADD-ONS GitHub Advanced Security Enterprise-grade security features Copilot for Business Enterprise-grade AI features Premium Support Enterprise-grade 24/7 … our input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly --> Name Query To see all available qualifiers, see our documentation . Cancel Create saved search Sign in Sign up Appearance settings Resetting focus You signed in with another tab or window. Reload to refresh your session. You signed out in another tab or window. Reload to refresh your session. You switched acc
%PDF-1.6 %���� 2410 0 obj >stream h���r�8���w��vv�c�``��H��)�дMB~[�6�Ed; }�=���4$m7�ݶ� �H�bݿ9|� �G|���: >%� �M���B�� h��I=0- �� @)D]+h���M�Y�FӣFj�f=h�IPi=ڄzmj�4�Qh��ϡ�y/���μ�ۄ �%h G,�pckj��s �� �1���x�t�$�v�y�p�� ��u�ap�� 4M9��л�_ r�s���S3緽�`|���C=�x��R6�e��\L�9iz �N� �� �^��� x ����W��K�}�� ^��9����}���� �K�,xf��`W�P97�e)�^�ˊ}���z`k7�+�vUn�m���'"s � sg4����2Ѱf7uƯp 3q �He3 P=�}|�����;���z �Dn�-��ˌo endstream endobj 2411 0 obj >stream h�Ḻ �0�_y[����`�R(�N ����P(� *K�� ����7%��Q�j�9� 0kh�~��������:�A� >stream hޜ��NC1 �_�o���HUF��bC �� .oO; ���.�����9T�� … 5-2400-c0d2ffff30cc xmp.did:2001271d-5632-4c8e-94c0-66db8152d7bd converted from application/x-indesign to application/pdf Adobe InDesign CC 13.1 (Macintosh) / 2019-08-27T15:55:57-04:00 xmp.id:eb68e689-b9c9-4c49-af07-3e9396180063 proof:pdf xmp.did:2001271d-5632-4c8e-94c0-66db8152d7bd uuid:09d007f8-ab10-174e-a718-a09854357fcd None 8.125" x 10.75" 7.875" x 10.5" 7.375" x 10" Adobe PDF Library 15.0 False 2019-08-27T19:55:57Z 2019-08-27T19:56:53Z Adobe InDesign CC 13.1 (Macintosh) … 7Z 2019-08-27T19:56:53Z Adobe InDesign CC 13.1 (Macintosh) 2019-08-27T19:56:53Z application/pdf 67435_A1_BBHBHF_C1-2_1-1.pdf PDF/X-1:2001 PDF/X-1a:2001 False PDF/X-1:2001 Minion Pro 2.030 0 0 Adobe Systems OpenType - PS 2771965578 MinionPro-Regular 2771965578 Roboto 2.001171 0 0 -- OpenType - TT 3551187176 Roboto-Black 3551187176 Roboto 2.001151 0 0 -- OpenType - TT 476580110 Roboto-Light 476580110 Roboto 2.001150 0 0 -- OpenType - TT 2673379806 Roboto-Bold 2673379806 Roboto … 5-2430-c0e2ffff5feb xmp.did:2001271d-5632-4c8e-94c0-66db8152d7bd converted from application/x-indesign to application/pdf Adobe InDesign CC 13.1 (Macintosh) / 2019-08-23T14:46:13-04:00 xmp.id:9c217d44-f04b-40ae-b70a-5b1f242fb317 proof:pdf xmp.did:2001271d-5632-4c8e-94c0-66db8152d7bd uuid:afc82831-169f-504a-b638-aa9a787dce3b None 8.125" x 10.75" 7.875" x 10.5" 7.375" x 10" Adobe PDF Library 15.0 False 2019-08-23T18:46:13Z 2019-08-23T18:52:49Z Adobe InDesign CC 13.1 (Macintosh) … 3Z 2019-08-23T18:52:49Z Adobe InDesign CC 13.1 (Macintosh) 2019-08-23T18:52:49Z application/pdf 67435_A1_BBHBHF_C2-1_1-1.pdf PDF/X-1:2001 PDF/X-1a:2001 False PDF/X-1:2001 Minion Pro 2.030 0 0 Adobe Systems OpenType - PS 2771965578 MinionPro-Regular 2771965578 Roboto 2.001171 0 0 -- OpenType - TT 3551187176 Roboto-Black 3551187176 Roboto 2.001151
Pulse 2.0 - Page 570 of 1274 - Business news, profiles, and deal flow coverage VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Archives Earnix Buying Insurance And Bank Focused GenAI Company Zelros By Amit Chowdhry ● May 2, 2025 Earnix, a leading Dynamic AI platform for Insurance, has signed a definitive agreement to acquire Zelros, a pioneer in Generative AI for insurers and banks. This collaboration will bring the power of predictive, generative, and agentic AI across the entire risk decisioning, personalization, and claims cycle, enabling pricing and underwriti … pacity expansion and strategic M&A to meet market demand. Ares: Private Markets Fund Surpasses $3 Billion In AUM In 3 Years By Amit Chowdhry ● May 2, 2025 Ares Management (a leading global alternative investment manager) announced that its Ares Private Markets Fund (APMF), a diversified private equity investment solution anchored in secondary investments, exceeded $3 billion in assets under management in its first three years in the market. APMF is distributed through Ares’ W … ke B Capital, Marunouchi Innovation Partners, BNP Paribas Solar Impulse Venture Fund, Citi Impact Fund, and Alumni Ventures. Rove Launches Universal Airlines Miles Program By Amit Chowdhry ● May 2, 2025 Universal airline miles program Rove Miles launched its platform with leading airlines, hotel partners, and over 7,000 merchants. And Rove was created from the ground up to help everyone take advantage of the discounts international loyalty programs provide, something traditio … Temasek Holdings, Breakthrough Energy Ventures, Builders Vision, Collaborative Fund, Earth Venture Capital, Lowercarbon Capital and S2G Investments; strategic investor BHP Ventures; global iron ore suppliers Rio Tinto and Roy Hill; leading electric arc furnace (EAF) steelmakers Nucor and Yamato Kogyo and organizations including Interfer Edelstahl and Toyota Tsusho, who are committed to reducing the environmental impact of iron and steel in their supply chains. Zarminali: Int … funding was led by Grenova investors, Peloton Equity and Hamilton Lane’s Impact Fund II, along with other existing investors. BOBO: Interview With Co-Founder Katherine Maslova About The Payment Solutions Company By Amit Chowdhry ● May 2, 2025 Bourgeois Bohème (BOBO) is a financial platform for ultra-high-net-worth individuals and family offices,
Amazon.com: Startup Assessment: Innovation Metrics: A Strategic Guide to Startup Assessment and Investment eBook : Karahan, Deniz: Kindle Store Skip to Main content About this item About this item About this item Buying options Compare with similar items Videos Reviews Keyboard shortcuts Search alt + / Cart shift + alt + C Home shift + alt + H Orders shift + alt + O Add to cart shift + alt + K Product summary shift + alt + D Show/Hide shortcuts shift + alt + Z To move between items, use your keyboard's up or down arrows. .us Delivering to Nashville 37217 Update location Kindle Store Selec … #x27;s Books All children's books Editors' Picks Teacher's Picks Award Winners Shorts Amazon Original Stories Short Reads Comics & Manga All Comics & Manga Comixology Home Comixology Unlimited Weekly New Releases Manga Comics Deals More Categories Special Editions Textbooks Magazines Amazon Classics Amazon First Reads Great on Kindle All Categories Top Categories Fiction Nonfiction Children's Books Shorts Comics & Manga More Categories Top Cate … #x27;s Books All children's books Editors' Picks Teacher's Picks Award Winners Shorts Amazon Original Stories Short Reads Comics & Manga All Comics & Manga Comixology Home Comixology Unlimited Weekly New Releases Manga Comics Deals More Categories Special Editions Textbooks Magazines Amazon Classics Amazon First Reads Great on Kindle New & Trending Recently Visited Featured Kindle eBooks Kindle Deals Best Books of 2025 New & Trending New Release … Sellers Amazon Best Sellers New York Times Best Sellers Amazon Charts Acclaimed Award Winners Goodreads Choice Winners From Our Editors Editors' Picks of the Month Amazon Book Review Best Books of 2025 Amazon Books Live Sarah Selects Book Club Memberships Recently Visited Featured Kindle eBooks Kindle Deals Best Books of 2025 Memberships Unlimited access to over 4 million digital books, audiobooks, comics, and magazines. Read or listen anywhere, anytime. Access over 700, … Sellers Amazon Best Sellers New York Times Best Sellers Amazon Charts Acclaimed Award Winners Goodreads Choice Winners From Our Editors Editors' Picks of the Month Amazon Book Review Best Books of 2025 Amazon Books Live Sarah Selects Book Club Memberships Tools Advanced Search Manage Content and Devices Improve Your Recommendations Your Comp
Advancing IIM Treatment with Restem-L Cell Therapy | RESTEM posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked
RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026 January 8, 2026 | 4 min read Twitter LinkedIn Facebook Email Print MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to m … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
%PDF-1.4 %���� 893 0 obj > endobj xref 893 12 0000000016 00000 n 0000001473 00000 n 0000001635 00000 n 0000001951 00000 n 0000002065 00000 n 0000002916 00000 n 0000003478 00000 n 0000003602 00000 n 0000004065 00000 n 0000004621 00000 n 0000001274 00000 n 0000000551 00000 n trailer ]/Prev 14438773/XRefStm 1274>> startxref 0 %%EOF 904 0 obj >stream h�b```b``���$W1�1 ��0p$1]PNmP`PP`f��-�� ��Gt}�K[-��R -ᷢIZ,&ǧ]a����� �d,�P�fq܁��A�(��Ic�Ā�� X]� ekQ[��������щM�>B���J�M�2�O �Ⱦv�2��M`s�����ի��3 ] �zho�i��i�R{�l��w�O P >/Filter/FlateDecode/Index[154 739]/Length 47/Size 893/Type/XRef … �*�s��� c��n���P.a�j�Dc$����nW{�}�䢛I�ō��f:�S>�}{#����$�����wB� s ����rFp��� 6wd�H!�+��O �U��?D�M�7[���y�� ��#7�{y�Ҋ>X �d�4?�K�# �)��}�e�bNJ� �T��D����WU-˒� i�.3� Zڤ��P;�x�� B; s�� (k;ݱ���YB��0�x oi��ԡ�r�`f@� ͎BBT����8JD�n�D����A@�mS( �P>�t� wa�]��L��G �֩��� I�")2� %���u�a�"R4K ��A!g~/��XN��MOI�$Ġk@W�v夷�q@$��0�r��^�2�lKg>���p�uÚ`�( ��5��A� ��DŽʍ�fG�$���J#Y����������/�_4 :.�l�g���Hȍ��:O{�m//��Ϧ��nmZI��h�i��=���� ���] … Z%>=&��)���ōW�|�iԉ�%S�T����Vi� �Z1>����ή����q͋6��y�ē�%�����s�R�������rFP��dt�+���) �Y��l�;y�,@���K�J��Ŵ�ou8��ǝ�E�5���Ac��0��$���S@V��T.�#RѨț߃�oDGB!\��[F$zոl\!�ּ�i_���dz�O�h\^�� �O��j5��? ��Ǖ���$���I�@�GFG�����-N��#0LGY��x��"�ó� �ǔ:%��\�����?��ᣧC����&B�[lB$���c1=9b������g�4]zS����2�J#M���3=sz2�d�)vj�b+��b+JAQ��v��DDQcg�V��j2�:�$=������?x ~ ��f��C��% ����|�~�{yy��t:���W_�|��"����H��;z�:;=> {�`�be.�V�ax4�M�-$�Ke0^�gĕJ��H�w� � … [}n���ÿ� ؚL�ȃ��*�H�M�w �ø�;G���s 0� ƀs[�4.~��A�Q��?R e��}t)w@��m��>�&0 RfP"��4$ �q��J (�>�9+ ?y�u����9��z�)|aG�u�� ug zi��f�O�R�~�W���jT�i8~b&>���j���ڏw��C��7�1 H�֕d��q��VO���t�(7J�j\�0�m���@\)��p��^8` �h!(F�$w4�I�.J4 L� �1� �: �4 P3G0�&��.�@xiN�$ �v����. �%�k�C=�)^L]��rAJF2�� F\T�� U��������������S-�� ��E� �@�`�Gd�r�ڬ.hm����J xdd���-�����͞eM�P*�~Ё@+Z� �ҡ���(��Y��� Z���)�Ä J�|��Px�Ҁ� … ��������������}����,�7%��lv��� �;+�O�KM�3���ZA �*��W�����w�?N�S��dv��/"�aW@rfP� �\��7)X�� ���f� E�z9cO|, ��Ņqx T皡���Y `(���� z�m|96l�M��T�T�K%Ð �4cВ� mMJ�������b� "R��I�� �9�cНڐ\*F�I�3L�`�*��)��JV�)��8 j)b�4���đ�{�6uC ��s�-��H &C��2C,Y�* ���B5N|ò�q���c@YMG��������,����Z�3�>pB+�I�B��� ��� �)�t�?ɡ!9 ]��sc�[� 7��aʭ��ɬ{$�?O=�) � �
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Restem v. JADI Cell: Federal Circuit Affirms Unpatentability of US9803176 | PatSnap | PatSnap Product AI AGENTS PatSnap Eureka Platform Agents for IP Agents for Engineering Agents for Life Sciences Agents for Materials PatSnap Eureka Desktop NEW AI APPLICATIONS Analytics IP Intelligence Synapse Biopharma Intelligence Bio Biosequence Search and Analysis Chemical Chemical Structure Search and Analysis OTHERS Open Platform NEW API, MCP & Integration Professional Services Eureka Desktop Now Available Download now Solutions INDUSTRIES Law Firms Life Sciences High-Tech USE CASES Competitor Tech Rese … rtiorari to the Supreme Court, a path rarely pursued and rarely granted in post-grant patent appeals. Case at a glance Case no. 23-2054 Plaintiff Restem, LLC Defendant JADI CELL, LLC Court Court of Appeals for the Federal Circuit Judge N/A Filed June 22, 2023 Closed March 4, 2025 Duration 621 days Outcome Unpatentable Verdict cause Patentability Basis Unpatentable Prior Art Intelligence See what prior art exists on this patent. Eureka scans millions of patents and papers to s … ll clinical derivation methods and therapeutic uses Publication No. US9803176B2 Application No. US13/732204 Patent details Product Methods and compositions for clinical derivation of allogenic cells for therapeutic use Cited in action June 22, 2023 Analyze US9803176B2 Check Prior Art See portfolio US9803176B2 (application number US13/732204) claims methods and compositions for the clinical derivation of allogenic cells — that is, cells sourced from a donor for therapeutic adm … ility in cell therapy and biotech Cases where the Federal Circuit affirmed post-grant unpatentability rulings in allogenic cell therapy, regenerative medicine, and related biologic composition patents. Cell therapy patent appeals Related patent case — similar technology Comparable case in the same technology domain. Patent holder and defendant reached resolution after proceedings. Settled PTAB cancellation affirmed Related infringement action — same court Comparable Methods a … rt risk for continuation prosecution Cancelled claims from inter partes or post-grant proceedings can inform prior art analyses in related continuation and divisional applications. Restem — or any assignee — prosecuting related applications covering allogenic cell derivation should expect examiners and future challengers to cite the cancellation
US8778679B2 - Umbilical cord lining stem cells and methods and material for isolating and culturing same - Google Patents US8778679B2 - Umbilical cord lining stem cells and methods and material for isolating and culturing same - Google Patents Umbilical cord lining stem cells and methods and material for isolating and culturing same Download PDF Info Publication number US8778679B2 US8778679B2 US13/668,138 US201213668138A US8778679B2 US 8778679 B2 US8778679 B2 US 8778679B2 US 201213668138 A US201213668138 A US 201213668138A US 8778679 B2 US8778679 B2 US 8778679B2 Authority US United States Prio … is and makes no representation as to the accuracy of the status listed.) Active Application number US13/668,138 Other versions US20130065302A1 ( en Inventor Francisco J. Silva Rafael Gonzalez Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Restem LLC Original Assignee Davinci Biosciences LLC Priority date (The priority date is an assumption and is not a … sted.) 2009-09-23 Filing date 2012-11-02 Publication date 2014-07-15 2012-11-02 Application filed by Davinci Biosciences LLC filed Critical Davinci Biosciences LLC 2012-11-02 Priority to US13/668,138 priority Critical patent/US8778679B2/en 2013-03-14 Publication of US20130065302A1 publication Critical patent/US20130065302A1/en 2014-02-24 Assigned to DAVINCI BIOSCIENCES LLC reassignment DAVINCI BIOSCIENCES LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assign … UMENT FOR DETAILS). Assignors: SILVA, FRANCISCO J., GONZALEZ, RAFAEL 2014-07-15 Application granted granted Critical 2014-07-15 Publication of US8778679B2 publication Critical patent/US8778679B2/en 2018-07-17 Assigned to REGENERATION WORLDWIDE COMPANY, INC. reassignment REGENERATION WORLDWIDE COMPANY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVINCI BIOSCIENCES LLC 2018-07-17 Assigned to RESTEM LLC reassignment RESTEM LLC ASSIGNMENT OF ASSI … preserving such cells. Description CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. application Ser. No. 13/497,497, filed Mar. 21, 2012, which is a national stage application of PCT/US2010/050025, filed on Sep. 23, 2010, which claims priority to U.S. Application Ser. No. 61/245,123, filed on Sep. 23, 2009. The d
U.S. FDA Grants Orphan Drug Designation for Restem’s ULSC Program for the Treatment of Dermatomyositis and Polymyositis - The Dermatology Digest Skip to content Subscribe Search Search Home News Videos Conference Coverage Podcasts Resource Centers Acne Alopecia Atopic Dermatitis Cosmetics Hidradenitis Suppurativa (HS) Pediatrics Pigment Disorders Practice Management Psoriasis Rare Diseases Rosacea Skin Cancer Vitiligo Home News Videos Conference Coverage Podcasts Resource Centers Acne Alopecia Atopic Dermatitis Cosmetics Hidradenitis Suppurativa (HS) Pediatrics Pigment Disorders Practice Manag
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy January 8, 2025 | 3 min read Twitter LinkedIn Facebook Email Print • Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data o … Restem-L could benefit from accelerated approval pathway, priority reviews, and rolling submissions, allowing us to bring this potentially life-changing treatment to IIM patients sooner. We look forward to advancing the Restem-L program development and initiating IIMPACT, a potentially registrational Phase 2/3 clinical trial in IIM in Q1 2025.” The FDA’s Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat seriou … approval, as well as eligibility for Accelerated Approval, Priority Review and Rolling Review if relevant criteria are met. 1 https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track About Idiopathic Inflammatory Myopathy (IIM) Idiopathic inflammatory myopathies (IIM) are a group of conditions characterized by inflammation of muscles (myositis) and other body systems. Polymyositis and dermatomyositis are subtypes of IIM. Po … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BIO International Convention | June 22-25, 2026 | San Diego Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung … nical Investigator Pathway Program Robert A. Winn Excellence in Clinical Trials Award Program linkedin Kristin M. Jones President and CEO Indiana Life Sciences Association Martin Jonsson, MSc CEO AlzeCure Pharma linkedin Ashutosh Joshi SVP of Commercial Operations Coherus Oncology Arlene Joyner Deputy Assistant Secretary and Director, Center for Industrial Base Management and Supply Chain Administration for Strategic Preparedness and Response (ASPR) DooYoung Jung, PhD CEO, Ph
RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L in Facioscapulohumeral Muscular Dystrophy - FSHD Society only used for Pushy, deprecated --> English English العربية Español de México Français du Canada 简体中文 Events Blog BetterLife Living with FSHD Understanding FSHD Diagnosis Early-onset FSHD Genetic Testing Symptoms FSHD University Physical Health Wellness Glossary of Scientific Terms Patient Library Genetic Cause Managing FSHD BetterLife FSHD Finding Care FSHD Navigator Newly Diagnosed with FSHD? FSHD Clinical Care Additional Resources Adaptive Equipment Coordinating … or Researchers International Research Congress BetterLife FSHD Research Gateway Apply for a Grant For Clinicians Continuing Education FSHD Masterclass Therapeutic Accelerator Project Mercury Global Innovation Hub About Us About the FSHD Society History Our Mission Our Impact Research We Have Funded Our Team Our Partners Financials Media Center Brand Guidelines News & Media Blog FSHD Research FSHD Society News Fundraising & Events General Living with FSHD Health and M … y inflammatory factors in related muscle inflammatory indications, and chose to fund this study after reviewing numerous other technologies and platforms. The initiation of this trial inches us closer to bringing hope to the up to 1 million patients estimated to suffer from FSHD worldwide.” The Phase 1/2a study ( NCT07086521 ) is a double-blind, randomized, dose-repeating, placebo-controlled, cross over study to assess the safety and preliminary efficacy of allogeneic UMPCs o … Research Therapeutic Accelerator Research & Clinical Trials For Clinicians Grant Opportunities Twitter Instagram Facebook YouTube LinkedIn Discord Blue Sky --> Facebook --> ©2026 FSHD Society. All Rights Reserved. Inclusivity and Equity Privacy Policy Financials Glossary Contact Us end of pushy container --> We've detected you might be speaking a different language. Do you want to change to: English English العربية Español de México Français du Canada 简体中文 Change La
RESTEM to Present at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM to Present at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference June 24, 2026 | 1 min read Twitter LinkedIn Facebook Email Print MIAMI, June 23, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Restem Group, Inc. - BIO Investment & Growth Summit 2026 Skip To Main Content February 16-17, 2027 | Miami Beach HOME ABOUT Show submenu for: ABOUT EVENT OVERVIEW WHY ATTEND? FAQS SHARE ON SOCIAL MEDIA CONTACT US SCHEDULE PROGRAM Show submenu for: PROGRAM PROGRAM SPEAKERS ADVISORY COMMITTEE COMPANY PRESENTATIONS PRESENTING COMPANIES BIO Partnering™ Show submenu for: BIO Partnering™ BIO PARTNERING™ PARTICIPATING COMPANIES PARTICIPATING INVESTORS PARTNERING WEBINARS DOWNLOAD THE APP LOG IN TO BIO PARTNERING SPONSOR Show submenu for: SPONSOR Become a Sponsor 2026 Sponsors SEARCH More Show mo
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy You are using an outdated browser. Please upgrade your browser to improve your experience. SUBMISSION GUIDELINES ABOUT US BACK ISSUES MEDIA PLANNER CONTACT FREE PRINT SUBSCRIPTION Login --> --> Subscriptions Current/Back Issues/eBooks Market News & Trends Executive Interviews --> Select a Section Analytical Testing Bioavailability & Solubility Bio Platforms Drug Delivery Injection Devices Excipients Formulation Development Contract Services Bio Platforms, Formulation Development, Market News & … Restem-L could benefit from accelerated approval pathway, priority reviews, and rolling submissions, allowing us to bring this potentially life-changing treatment to IIM patients sooner. We look forward to advancing the Restem-L program development and initiating IIMPACT, a potentially registrational Phase 2/3 clinical trial in IIM in Q1 2025.” The FDA’s Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat seriou … approval, as well as eligibility for Accelerated Approval, Priority Review and Rolling Review if relevant criteria are met. Idiopathic inflammatory myopathies (IIM) are a group of conditions characterized by inflammation of muscles (myositis) and other body systems. Polymyositis and dermatomyositis are subtypes of IIM. Polymyositis causes inflammation and weakness of the skeletal muscles responsible for movement. Dermatomyositis is a form of polymyositis that is associated w … Late Stage Customization PCI’s Paul Smallman and Michelle D’Angelo explore the application and opportunities for leveraging advanced technologies in late stage customization and its potential to benefit pharmaceutical and biotech companies in gaining competitive advantage in their global supply chain. Learn More > A Guide to Aseptic Manufacturing The aseptic manufacturing process is complex with each drug candidate's unique set of challenges. Speed to market is necessary, … by WalkerTek . Don’t miss out on this exclusive content! Fill out the form and submit today Fill out the form below to access this exclusive content. --> Close this module
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Restem at The BIO Investment & Growth Summit at Eden Roc Miami Beach Hotel - World Red Eye | World Red Eye --> --> --> --> --> --> Categories Featured News Video About Categories Nightlife Celebrity News Food Fashion Music Lifestyle Culture Tech Featured News guide Video Philosophy Client Log In search client Client login facebook Twitter Instagram Newsletter 0-458-21 0-458-22 0-458-62482 0-458-11 0-458-46935 0-458-181747 Celebrity See all Celebrity Ty Dolla $ign, Young Thug, & Kodak Black at LIV 50 Cent, Young M.A, & Mack Maine at LIVONSUNDAY WRE News: John Summit Set
Restem About Us Our Science Programs Restem-L rESTEM-x a NK Program Our Pipeline Clinical Trials Idiopathic Inflammatory Myopathy Rheumatoid Arthritis Facioscapulohumeral Muscular Dystrophy Culture Contact Us Investors & Media Press Releases Publications Corporate Presentation & EVENTS About RESTEM We are a passionate team dedicated to restoring health through innovation At its core, RESTEM’s science focuses on modulating the immune system to treat a wide range of inflammatory-driven diseases. RESTEM Group is a clinical-stage biotechnology company with a groundbreaking adult stem cell t … ytopenia. Earlier in his career, Nelson held senior audit and advisory roles at Grant Thornton LLP and Ernst & Young, where he led high-stakes audits and transaction advisory services for global clients across various industries. Nelson is a recognized leader with deep expertise in managing cross-functional teams, developing financial strategies, and supporting commercial launches in the biotech industry. Nelson Cabatuan Chief Financial Officer Read Bio Bärbel Eppler-Moss … mp; Cancer Institute Baptist Hospital An internationally renowned expert in the application of both autologous and allogeneic stem cell transplantation for the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, Guenther Koehne, M.D., Ph.D., serves as deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, part of Baptist Health South Florida. Prior to j … s a resident in internal medicine. He completed an additional internal medicine residency at Rush University Medical Center in Chicago. His extensive training also includes a medical oncology/hematology fellowship at Memorial Sloan Kettering Cancer Center and a research fellowship in the Immunology Program at the Sloan Kettering Institute for Cancer Research, Allogeneic Bone Marrow Transplantation Service. Dr. Koehne is a member of the American Society of Hematology, American … ed a number of awards including the Doris Duke Distinguished Clinical Scientist Award and is a member of the Association of American Physicians. He was previously the President of the International Society of Cellular Therapy and the American Society of Blood and Marrow Transplantation. He served as an Associate Editor of the journal Blood and is
Home About Us Our Science Programs Restem-L rESTEM-x a NK Program Our Pipeline Clinical Trials Idiopathic Inflammatory Myopathy Rheumatoid Arthritis Facioscapulohumeral Muscular Dystrophy Culture Contact Us Investors & Media Press Releases Publications Corporate Presentation & EVENTS Restoring Immunity. advancing cell therapy. Modulating Immune Response Through Advanced Cell Therapeutics We are advancing the future of immune health by harnessing advanced cell-based therapeutics to treat inflammatory-driven diseases. By tapping into the body’s natural ability to restore balance, we’re tr
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Press Releases About Us Our Science Programs Restem-L rESTEM-x a NK Program Our Pipeline Clinical Trials Idiopathic Inflammatory Myopathy Rheumatoid Arthritis Facioscapulohumeral Muscular Dystrophy Culture Contact Us Investors & Media Press Releases Publications Corporate Presentation & EVENTS Investors & Media Press Releases Press Releases Publications Corporate Presentation & eVENTS June 23, 2026 RESTEM to Present at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire June 17, 2026 RESTEM to Present at BIO International Convention GlobeNewswire February 23
RESTEM to Participate in the 15th LifeSci Partners --> Accessibility: Skip TopNav RESTEM to Participate in the 15th LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference in January 2026 December 18, 2025 08:00 ET | Source: Restem Restem MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its management team will participate in the 15 th LifeSci Partners Corporate Access event taking place January 12-1
RESTEM to Participate in the 15th LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference in January 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases RESTEM to Participate in the 15th LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference in January 2026 December 19, 2025 | 1 min read Twitter LinkedIn Facebook Email Print MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that dev … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Restem Group Inc. - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our maili … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Corporate Presentations About Us Our Science Programs Restem-L rESTEM-x a NK Program Our Pipeline Clinical Trials Idiopathic Inflammatory Myopathy Rheumatoid Arthritis Facioscapulohumeral Muscular Dystrophy Culture Contact Us Investors & Media Press Releases Publications Corporate Presentation & EVENTS Investors & Media Corporate Presentation & eVENTS Press Releases Publications Corporate Presentation & eVENTS Corporate Presentation Download Events June 30, 2026 11:00 AM EDT Virtual Event Company Presentation at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
RESTEM to Present at BIO International Convention --> Accessibility: Skip TopNav RESTEM to Present at BIO International Convention June 17, 2026 12:00 ET | Source: Restem Restem MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that CEO, Andres Isaias, will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. Date and Time: Tuesday, June 23, 2026, at 10:30 am PT Format: Corporate presentati
Restem Group Inc. - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our maili … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung